See more : Nichias Corporation (5393.T) Income Statement Analysis – Financial Results
Complete financial analysis of Avadel Pharmaceuticals plc (AVDL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avadel Pharmaceuticals plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- CVW CleanTech Inc. (TITUF) Income Statement Analysis – Financial Results
- PT Astra Agro Lestari Tbk (AALI.JK) Income Statement Analysis – Financial Results
- JLEN Environmental Assets Group Limited (JLEN.L) Income Statement Analysis – Financial Results
- Electric Last Mile Solutions, Inc. (ELMWQ) Income Statement Analysis – Financial Results
- Rouchon Industries, Inc. (RCHN) Income Statement Analysis – Financial Results
Avadel Pharmaceuticals plc (AVDL)
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.96M | 0.00 | 0.00 | 22.33M | 59.22M | 103.27M | 172.74M | 150.25M | 173.21M | 14.78M | 22.44M | 26.10M | 32.60M | 37.09M | 42.12M | 38.62M | 36.65M | 23.02M | 23.60M | 55.41M | 25.17M | 18.41M | 13.09M | 10.90M | 11.04M | 9.52M | 8.10M | 4.90M |
| Cost of Revenue | 846.00K | 1.49M | 815.00K | 5.74M | 12.13M | 17.52M | 16.30M | 13.25M | 10.92M | 3.38M | 4.35M | 5.86M | 6.28M | 6.91M | 10.12M | 9.62M | 17.32M | 6.25M | 2.53M | 3.60M | 3.68M | 2.37M | 2.17M | 1.75M | 2.09M | 3.53M | 3.10M | 400.00K |
| Gross Profit | 27.12M | -1.49M | -815.00K | 16.59M | 47.09M | 85.75M | 156.44M | 137.00M | 162.29M | 11.39M | 18.09M | 20.24M | 26.32M | 30.18M | 32.00M | 29.00M | 19.33M | 16.77M | 21.07M | 51.81M | 21.49M | 16.03M | 10.92M | 9.15M | 8.95M | 5.99M | 5.00M | 4.50M |
| Gross Profit Ratio | 96.97% | 0.00% | 0.00% | 74.29% | 79.52% | 83.04% | 90.56% | 91.18% | 93.69% | 77.10% | 80.62% | 77.55% | 80.72% | 81.36% | 75.98% | 75.09% | 52.75% | 72.85% | 89.30% | 93.50% | 85.39% | 87.11% | 83.45% | 83.95% | 81.10% | 62.90% | 61.73% | 91.84% |
| Research & Development | 13.26M | 20.70M | 17.10M | 20.44M | 32.92M | 39.33M | 34.22M | 34.61M | 25.61M | 17.30M | 26.69M | 26.12M | 25.09M | 28.69M | 30.42M | 36.25M | 43.56M | 38.23M | 47.30M | 35.36M | 20.22M | 12.24M | 10.66M | 9.79M | 11.05M | 10.61M | 10.10M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 151.71M | 74.52M | 68.50M | 32.41M | 30.18M | 100.36M | 58.86M | 44.18M | 21.71M | 15.70M | 13.31M | 14.15M | 10.81M | 11.33M | 13.34M | 12.91M | 16.63M | 17.38M | 14.54M | 7.61M | 5.97M | 4.02M | 3.41M | 3.46M | 3.69M | 3.63M | 3.20M | 12.60M |
| Other Expenses | 0.00 | 3.35M | 217.00K | 406.00K | 816.00K | 1.90M | 2.09M | -6.55M | 0.00 | -36.00K | 573.00K | 102.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 164.97M | 95.22M | 85.60M | 53.25M | 63.92M | 146.31M | 96.74M | 92.68M | 59.88M | 44.75M | 39.99M | 40.27M | 35.90M | 40.02M | 43.75M | 49.16M | 60.18M | 55.61M | 61.84M | 42.97M | 26.19M | 16.26M | 14.08M | 25.26M | 15.95M | 15.28M | 14.00M | 13.50M |
| Cost & Expenses | 165.81M | 95.22M | 85.60M | 59.00M | 76.04M | 163.82M | 113.04M | 105.93M | 70.81M | 48.13M | 44.34M | 46.13M | 42.18M | 46.93M | 53.87M | 58.78M | 77.50M | 61.86M | 64.37M | 46.58M | 29.87M | 18.63M | 16.24M | 27.01M | 18.04M | 18.81M | 17.10M | 13.90M |
| Interest Income | 0.00 | 11.12M | 2.13M | 12.59M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 963.00K | 254.00K | 629.00K | 667.00K | 464.00K | 525.00K | 1.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.89M | 12.34M | 9.94M | 12.99M | 12.48M | 10.62M | 1.05M | 963.00K | 6.30M | 9.27M | 4.35M | 118.00K | 73.00K | 24.00K | 100.00K | 18.00K | 16.00K | 35.00K | 68.00K | 45.00K | 29.00K | 49.00K | 52.00K | 51.00K | 0.00 | 95.00K | 0.00 | 100.00K |
| Depreciation & Amortization | 1.77M | 1.49M | 815.00K | 1.69M | 2.49M | 7.43M | 4.88M | 14.49M | 13.13M | 14.14M | 3.06M | 3.18M | 3.35M | 4.70M | 5.92M | 7.25M | 6.20M | 5.64M | 4.74M | 2.53M | 1.71M | 1.46M | 1.27M | 1.11M | 1.21M | 1.04M | 700.00K | 900.00K |
| EBITDA | -149.13M | -97.60M | -84.78M | -34.97M | -23.61M | -95.15M | 65.89M | 5.73M | 115.54M | -94.74M | -50.03M | -8.36M | -5.16M | -4.05M | -5.42M | -11.30M | -33.22M | -33.20M | -36.03M | 9.34M | -2.99M | 1.24M | -1.89M | -14.99M | -5.79M | -8.25M | -8.30M | -8.10M |
| EBITDA Ratio | -533.29% | 0.00% | 0.00% | -141.52% | -24.22% | -51.44% | 37.39% | 39.14% | 66.70% | -123.76% | -95.02% | -139.41% | -30.64% | -28.24% | -27.64% | -29.72% | -93.83% | -142.19% | -175.99% | 20.77% | -12.30% | -6.47% | -14.82% | -137.98% | -53.73% | -85.84% | -111.11% | -179.59% |
| Operating Income | -137.85M | -98.56M | -85.55M | -36.66M | -16.83M | -104.93M | 88.30M | -4.97M | 71.45M | -93.86M | -50.03M | -3.49M | -9.58M | -9.84M | -11.75M | -20.16M | -40.85M | -38.84M | -40.77M | 8.84M | -4.70M | -223.00K | -3.16M | -16.11M | -7.00M | -9.29M | -9.00M | -9.00M |
| Operating Income Ratio | -492.97% | 0.00% | 0.00% | -164.15% | -28.42% | -101.60% | 51.12% | -3.30% | 41.25% | -635.24% | -222.93% | -13.36% | -29.40% | -26.53% | -27.90% | -52.20% | -111.44% | -168.71% | -172.76% | 15.94% | -18.67% | -1.21% | -24.11% | -147.74% | -63.41% | -97.57% | -111.11% | -183.67% |
| Total Other Income/Expenses | -22.93M | -12.88M | -7.60M | -10.90M | -14.47M | -8.27M | 3.16M | -4.75M | 6.26M | 3.33M | -4.06M | 1.98M | 1.00M | 1.07M | 314.00K | 1.60M | 1.42M | 1.52M | 9.11M | 463.00K | 272.00K | 2.68M | 295.00K | 11.27M | 322.00K | 232.00K | 800.00K | 600.00K |
| Income Before Tax | -160.78M | -111.44M | -93.15M | -5.08M | -38.58M | -113.20M | 91.47M | -9.72M | 78.39M | -90.33M | -54.10M | -7.93M | -8.58M | -8.77M | -11.44M | -18.56M | -39.43M | -37.32M | -31.66M | 9.30M | -4.00M | 2.45M | -2.86M | -4.83M | -6.68M | -9.06M | -8.20M | -8.40M |
| Income Before Tax Ratio | -574.96% | 0.00% | 0.00% | -22.75% | -65.16% | -109.61% | 52.95% | -6.47% | 45.26% | -611.38% | -241.03% | -30.38% | -26.33% | -23.63% | -27.16% | -48.06% | -107.58% | -162.12% | -134.18% | 16.78% | -15.88% | 13.32% | -21.85% | -44.34% | -60.49% | -95.14% | -101.23% | -171.43% |
| Income Tax Expense | -501.00K | 26.03M | -15.82M | -12.11M | -5.36M | -17.89M | 24.22M | 31.56M | 37.74M | -1.41M | -11.17M | -4.70M | 192.00K | 209.00K | -6.23M | -6.48M | -1.69M | -2.12M | -4.29M | -3.20M | -503.00K | -553.00K | 14.00K | 50.00K | 16.00K | -1.25M | -1.40M | -1.50M |
| Net Income | -160.28M | -137.46M | -77.33M | 7.03M | -33.23M | -95.30M | 67.25M | -41.28M | 40.66M | -84.91M | -42.93M | -3.23M | -8.77M | -8.98M | -11.44M | -12.08M | -37.74M | -35.20M | -27.38M | 12.50M | -3.49M | 3.01M | -2.87M | -9.46M | -6.69M | -7.81M | -6.80M | -6.90M |
| Net Income Ratio | -573.17% | 0.00% | 0.00% | 31.47% | -56.11% | -92.29% | 38.93% | -27.47% | 23.47% | -574.66% | -191.26% | -12.37% | -26.91% | -24.20% | -27.16% | -31.29% | -102.95% | -152.91% | -116.01% | 22.56% | -13.88% | 16.33% | -21.96% | -86.78% | -60.63% | -82.04% | -83.95% | -140.82% |
| EPS | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 | -2.55 | 1.66 | -1.00 | 1.00 | -2.34 | -1.69 | -0.13 | -0.36 | -0.37 | -0.47 | -0.50 | -1.57 | -1.48 | -1.19 | 0.58 | -0.20 | 0.19 | -0.18 | -0.62 | -0.52 | -0.65 | -0.65 | -0.80 |
| EPS Diluted | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 | -2.55 | 1.61 | -1.00 | 0.93 | -2.34 | -1.69 | -0.13 | -0.36 | -0.37 | -0.47 | -0.50 | -1.57 | -1.48 | -1.19 | 0.53 | -0.20 | 0.18 | -0.18 | -0.62 | -0.52 | -0.65 | -0.65 | -0.80 |
| Weighted Avg Shares Out | 80.17M | 60.09M | 58.54M | 53.00M | 37.40M | 37.33M | 40.47M | 41.25M | 40.58M | 36.21M | 25.41M | 24.95M | 24.67M | 24.41M | 24.23M | 24.08M | 24.02M | 23.81M | 23.00M | 21.51M | 17.76M | 16.20M | 16.20M | 15.33M | 12.94M | 12.05M | 10.46M | 8.63M |
| Weighted Avg Shares Out (Dil) | 80.17M | 60.09M | 58.54M | 54.94M | 37.40M | 37.33M | 41.77M | 41.25M | 43.62M | 36.21M | 25.45M | 25.09M | 24.67M | 24.41M | 24.23M | 24.08M | 24.02M | 23.81M | 23.00M | 23.56M | 17.76M | 16.71M | 16.20M | 15.33M | 12.94M | 12.05M | 10.46M | 8.63M |
Avadel Pharmaceuticals Issues Statement On Patent Litigation
DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today issued a statement in response to a jury ruling from the United States District Court for the District of Delaware (“Court”) in a patent suit brought...
Avadel Pharmaceuticals plc (AVDL) Q4 2023 Earnings Call Transcript
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q4 2023 Earnings Conference Call March 4, 2024 7:30 AM ET Company Participants Austin Murtagh - Stern IR Gregory Divis - CEO Richard Kim - Chief Commercial Officer Thomas McHugh - CFO Conference Call Participants...
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-- Generated $19.5 million in fourth quarter and $28.0 million of full year 2023 net revenue from sales of LUMRYZ™ -- -- As of January 31 st , greater than 2,200 patients enrolled in RYZUP TM and more than 1,200...
Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Avadel Pharmaceuticals has made good progress with the launch of Lumryz, enrolling 1,900 patients and generating $19 million in Q4 net sales. Legal risks from competitor Jazz Pharmaceuticals remain a concern, with ongoing litigation and the potential for Lumryz to...
Here's Why You Should Invest in Avadel (AVDL) Stock Now
Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.
Avadel (AVDL) is a Great Momentum Stock: Should You Buy?
Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.
How Much Upside is Left in Avadel (AVDL)? Wall Street Analysts Think 37.36%
The consensus price target hints at a 37.4% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside...
Why Avadel Pharmaceuticals (AVDL) Stock Might be a Great Pick
Avadel Pharmaceuticals (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Avadel May Continue To Outperform With Positive Launch Momentum
Avadel Pharma's launch of its product LUMRYZ is expected to drive the company's stock performance. LUMRYZ appears to have momentum and is differentiated from current narcolepsy treatments. The potential revenue for Avadel from LUMRYZ could ultimately range from $500 million...
Avadel Pharmaceuticals PLC (AVDL) Q3 2023 Earnings Call Transcript
Avadel Pharmaceuticals PLC (NASDAQ:AVDL ) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Austin Murtagh - Stern Investor Relations Gregory Divis - CEO & Director Richard Kim - Chief Commercial Officer Jennifer Gudeman - SVP,...
Source: https://incomestatements.info
Category: Stock Reports